Physician profile
Rose David
NPI 1245876960
$3,598.62
in general payments reported to CMS, 2019-2025
28 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $603 · 2024: $1,172 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.09 |
| Education | $144.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $387.19 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $341.42 | 2024-2025 | |
| Amgen INC. | $322.21 | 2023-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $300.32 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.29 | 2022-2025 | |
| Lilly USA, LLC | $203.19 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $198.29 | 2022-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $189.22 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Novo Nordisk INC | $175.77 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Scpharmaceuticals INC. | $171.69 | 2025 | |
| Chiesi USA, INC. | $151.65 | 2024 | Elfabrio |
| Opko Pharmaceuticals, LLC | $144.08 | 2023-2024 | Rayaldee |
| Atricure, INC. | $127.35 | 2023 | |
| Ardelyx, INC. | $85.35 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $77.48 | 2025 | Vafseo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.82 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $54.44 | 2023-2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $53.69 | 2023 | Gattex |
| Apellis Pharmaceuticals, INC. | $51.73 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $51.12 | 2024-2025 | Onpattro, Oxlumo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.49 | 2024-2025 | |
| Cormedix INC. | $46.21 | 2024-2025 | Defencath, Defencath |
| Aurinia Pharma U.S., INC. | $35.13 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $24.92 | 2024 | Jynarque |
| Cycle Pharmaceuticals INC | $24.30 | 2024 | Tiopronin |
| Xeris Pharmaceuticals, INC. | $21.78 | 2024 | Keveyis |
| Pfizer INC. | $16.99 | 2024 | |
| Glaxosmithkline, LLC. | $13.50 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.